ErVimmune
ErVimmune develops cancer vaccines and T cell therapies targeting cold tumors using AI-driven antigen discovery.
About ErVimmune
ErVimmune creates novel immunotherapies that target non-conventional tumor antigens that are abnormally expressed in cancer cells and shared by tumors and patients, with a particular emphasis on meeting unmet medical requirements in cold malignancies.
Company Facts
- Headquarters
- Lyon
- Founded
- 2019
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- early_stage_venture
- Total Funding
- $27,673,257
- Last Funding Type
- series_a
- Last Funding Date
- 2026-01-21
- Website
- https://ervimmune.com
Industries & Categories
Biopharma, Biotechnology, Oncology
Social Links
Canonical: https://fsome.com/organization/ervimmune-49100 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.